<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727633</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0304</org_study_id>
    <secondary_id>2017-004859-22</secondary_id>
    <secondary_id>UF 9888</secondary_id>
    <nct_id>NCT03727633</nct_id>
  </id_info>
  <brief_title>Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion</brief_title>
  <acronym>LIDA-BII</acronym>
  <official_title>Traitement Des Carcinomes hépatocellulaires Sur Cirrhose Child A/B7 Par Injection Intra-artérielle hépatique d'Une émulsion de Lipiodol et Idarubicine : Etude de Phase II, Monobras, Multicentrique.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose in this trial to test a hepatic chemotherapy, consisting of the
      hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol, lipid vector, without
      embolization in the treatment of non-metastatic, unresectable hepatocellular carcinoma on
      cirrhosis with Child-Pugh A/B7.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The purpose of this study is to assess efficacy and tolerance of hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol for treatment of non-metastatic, unresectable hepatocellular carcinoma on cirrhosis with Child-Pugh A/B7.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking is used. All involved know the identity of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants presenting a disease control at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>The primary outcome is to evaluate the disease control rate (partial, complete or stable response) 4 months after the first cycle of chemo-lipiodol using mRECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of chemo-lipiodol defined by NCI-CTCAE version 4.03</measure>
    <time_frame>12 months</time_frame>
    <description>Safety defined by NCI-CTCAE version 4.03 published 14 june 2010</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate of chemo-lipiodol</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate according to mRECIST at 6 months after the first cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best response at 6 months after the first cycle of chemo-lipiodol according to mRECIST</measure>
    <time_frame>6 months</time_frame>
    <description>The best response according to mRECIST at 6 months after the first cycle of chemo-lipiodol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival at 12 months after the first cycle of chemo-lipiodol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (QLQ) QLQ-C30</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life questionnaire at 12 months after the first cycle of chemo-lipiodol (QLQ-C30). Subscale minimum score is egal to 1 (not at all) and maximum score is egal to 4 (very much). The maximal score correspond to a better quality of life. Subscales are summed to compute a total score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin and Lipiodol</intervention_name>
    <description>Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-proven HCC or according to EASL criteria

          -  Child-Pugh A or B7

          -  Disease that is not suitable for resection, ablation or radiofrequency

          -  Performance Status ECOG 0 or 1

          -  BCLC A/B or C if Performance Status ECOG = 1

          -  Measurable lesions according to mRECIST criteria

          -  No previous treatment with chemotherapy, radiotherapy or transarterial embolization
             (with or without chemotherapy) or radioembolisation

          -  Age superior or equal to 18 years

          -  Platelets &gt; 50,000/mm3, Polynuclear neutrophils &gt; 1000/mm3, Creatininemia &lt; 150umol/L,
             Bilirubinemia &lt; 5 mg/dL

          -  Absence of heart failure (Ultrasound LVEF &gt; 50%)

          -  Women of child-bearing age using an adequate method of contraception throughout
             treatment

          -  Men using an adequate method of contraception throughout the treatment and at least 3
             months after the end of treatment

          -  Written informed consent

          -  National health insurance cover

        Exclusion Criteria:

          -  Advanced tumor disease (extrahepatic except pulmonary micronodules &lt;7mm of tumoral
             portal vein thrombosis on positron emission tomography are not a contra-indication.)

          -  Large HCC with liver invasion &gt;50%

          -  History of other cancer than HCC and excluding cancers known to have been cured for
             more than 5 years, or basocellular skin tumors or cervical cancer in situ treated with
             adequate and curative purpose

          -  Advanced liver disease (Child B8, B9 or C)

          -  Contra-indication for the MRI (Pacemaker or neurosensorial stimulator or implantable
             defibrillator, cochlear implant, ferromagnetic foreing body similar to the nervous
             structure)

          -  Contra-indication to the injection of the gadolinium-based contrast agents (history of
             hypersensibility to the gadolinium chelates, meglumine).

          -  Contra-indication to idarubicin (Hypersensibility to active substance or excipients,
             cardiopathy with myocardial insufficiency of less than 6 months, serious arrhythmias,
             serious renal or liver failure, yellow fever vaccine or any other live attenuated
             vaccine, persistente myelosuppression, previous treatments with idarubicin and/or
             other anthracyclines or anthracenediones at maximum cumulative doses, stomatitis)

          -  Contra-indication to Lipiodol (Hypersensibility, proven hyperthyroidism, tromatic
             injuries, bleeding or recent bleeding)

          -  Concomitant disease or uncontrolled severe clinical situation

          -  Uncontrolled severe infection

          -  Vascular anatomy makes it impossible to perform hepatic intra-arterial treatments

          -  Pregnancy (Beta HCG positive) or breastfeeding

          -  Patient who for psychological, social, family or geographical reasons cannot be
             followed regularly

          -  Vulnerable person

          -  Concomitant participation of the patient in another research involving the human
             person
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris GUIU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris GUIU, MD</last_name>
    <phone>04 67 33 75 46</phone>
    <email>b-guiu@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe AUBE, PH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romaric LOFFROY, PH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris GUIU, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick CHEVALLIER, PH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

